LLY

1,135.81

-0.49%↓

JNJ

238.82

+1.16%↑

ABBV

225.92

+0.44%↑

UNH

405.52

-1.41%↓

MRK

117.87

-1.43%↓

LLY

1,135.81

-0.49%↓

JNJ

238.82

+1.16%↑

ABBV

225.92

+0.44%↑

UNH

405.52

-1.41%↓

MRK

117.87

-1.43%↓

LLY

1,135.81

-0.49%↓

JNJ

238.82

+1.16%↑

ABBV

225.92

+0.44%↑

UNH

405.52

-1.41%↓

MRK

117.87

-1.43%↓

LLY

1,135.81

-0.49%↓

JNJ

238.82

+1.16%↑

ABBV

225.92

+0.44%↑

UNH

405.52

-1.41%↓

MRK

117.87

-1.43%↓

LLY

1,135.81

-0.49%↓

JNJ

238.82

+1.16%↑

ABBV

225.92

+0.44%↑

UNH

405.52

-1.41%↓

MRK

117.87

-1.43%↓

Kodu・Aktsiate loetelu・Denali Therapeutics Inc

Denali Therapeutics Inc

Avatud

SektorTervishoid

20.64 5.09

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

19.39

Max

21.71

Põhinäitajad
By Trading Economics
Sissetulek	102K -128M
Aktsiakasum	-0.69
Töötajad	507
EBITDA	-9.8M -135M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+81.68% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	7. aug 2026

Turustatistika
By TradingEconomics
Turukapital	136M 3.1B
Eelmine avamishind	15.55
Eelmine sulgemishind	20.64

Uudiste sentiment

By Acuity

27%

73%

61 / 344 Pingereas Healthcare

Denali Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

9. juuni 2026, 23:49 UTC

Market Talk

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

9. juuni 2026, 23:45 UTC

Omandamised, ülevõtmised, äriostud

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

9. juuni 2026, 23:44 UTC

Omandamised, ülevõtmised, äriostud

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

9. juuni 2026, 23:44 UTC

Omandamised, ülevõtmised, äriostud

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

9. juuni 2026, 23:43 UTC

Omandamised, ülevõtmised, äriostud

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

9. juuni 2026, 23:35 UTC

Market Talk

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

9. juuni 2026, 22:06 UTC

Omandamised, ülevõtmised, äriostud

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

9. juuni 2026, 22:05 UTC

Omandamised, ülevõtmised, äriostud

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

9. juuni 2026, 22:05 UTC

Omandamised, ülevõtmised, äriostud

Samsung: Additional Investment Makes It Largest Shareholder in Element

9. juuni 2026, 22:05 UTC

Omandamised, ülevõtmised, äriostud

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

9. juuni 2026, 20:51 UTC

Tulu

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

9. juuni 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

9. juuni 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. juuni 2026, 20:09 UTC

Market Talk

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

9. juuni 2026, 19:36 UTC

Market Talk

Cattle Climbs as Crude Oil Falls -- Market Talk

9. juuni 2026, 19:32 UTC

Market Talk

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

9. juuni 2026, 19:25 UTC

Market Talk

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

9. juuni 2026, 19:00 UTC

Market Talk

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

9. juuni 2026, 18:52 UTC

Omandamised, ülevõtmised, äriostud

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

9. juuni 2026, 18:47 UTC

Market Talk

No World Cup Inflation Seen So Far in Mexico -- Market Talk

9. juuni 2026, 18:37 UTC

Market Talk

Canada's Cooling Trade With the U.S. -- Market Talk

9. juuni 2026, 18:27 UTC

Market Talk

Precious Metals Lower as Trump Vows Military Response -- Market Talk

9. juuni 2026, 17:35 UTC

Market Talk

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

9. juuni 2026, 17:30 UTC

Market Talk

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

9. juuni 2026, 16:34 UTC

Market Talk

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

9. juuni 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9. juuni 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. juuni 2026, 16:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Health Care Roundup: Market Talk

9. juuni 2026, 15:28 UTC

Market Talk

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

9. juuni 2026, 15:25 UTC

Market Talk

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Denali Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

81.68% tõus

12 kuu keskmine prognoos

Keskmine 35.5 USD 81.68%

Kõrge 42 USD

Madal 23 USD

Põhineb 13 Wall Streeti analüütiku instrumendi Denali Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

13 ratings

Osta

Hoia

Müü

Põhineb 13 analüütiku instrumendi Denali Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

61 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.